BCMA Test Your Knowledge

Test Your Knowledge

Quiz: How Do Patients With MM Who Received Anti-BCMA Therapy Respond to COVID-19 Vaccinations?

12/01/2021

True or false: Patients with MM who received anti-BCMA antibody-based therapy were associated with having a lack of T-cell responses following SARS-CoV-2 vaccination.

True or false: Patients with MM...

12/01/2021

Oncology

Quiz

Quiz: Which of the Following Inhibitors Target BCMA in MM?

11/10/2021

Which of the following inhibitors showed an increase in BCMA surface density and a decrease in soluble BCMA levels?

Which of the following...

11/10/2021

Oncology

Test Your Knowledge

Quiz: Is Extramedullary Disease Associated with Poor Prognoses in R/R MM?

11/02/2021

True or false: In R/R MM, extramedullary disease is linked to significantly poor prognoses.

True or false: In R/R MM,...

11/02/2021

Oncology

Quiz

Quiz: Can Anti-BCMA CAR-T Cell Therapy Cause Humoral Immune Deficiencies in R/R MM?

10/14/2021

True or false: A profound and lasting humoral immune deficiency was found after anti-BCMA CAR-T cell therapy in patients with R/R MM.

True or false: A profound and...

10/14/2021

Oncology

Test Your Knowledge

Quiz: Which Cell Type is Known for BCMA Expression?

09/20/2021

Which of the following cell type is known for BCMA expression?

Which of the following cell type...

09/20/2021

Oncology

Test Your Knowledge

Quiz: Responses to BCMA-Directed CAR-T Therapy for R/R MM

09/07/2021

True or false: Results from the CARTITUDE-1 trial showed that BCMA-directed CAR-T therapy yielded early, deep, and durable responses in patients with R/R MM.

True or false: Results from the...

09/07/2021

Oncology

Test Your Knowledge

Quiz: Does Teclistamab Therapy Display Promise in BCMA-Positive MM?

11/19/2020

True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.

True or False: Data suggest that...

11/19/2020

Oncology

Test Your Knowledge

Quiz: The Basics of BCMA Expression in Multiple Myeloma

10/08/2020

True or False: BCMA is expressed in nearly all MM tumor cells and serves as a potential biomarker for identifying malignant plasma cells in this patient population.

True or False: BCMA is expressed...

10/08/2020

Oncology

Test Your Knowledge

Quiz: Promising Role of BCMA-Directed CAR-T Therapy for R/R MM

09/25/2020

True or False: According to data from the CARTITUDE-1 trial, the BCMA-directed CAR-T therapy JNJ‑4528 was very effective and yielded 100% overall response rate in patients with relapsed or refractory MM.

True or False: According to data...

09/25/2020

Oncology

Test Your Knowledge

Quiz: Can BCMA-Targeting CAR T-Cells Improve Patient Outcomes in MM?

08/26/2020

True or False: Multiple studies have demonstrated positive results with BCMA-targeting CAR T-cells for the treatment of relapsed and refractory MM.

True or False: Multiple studies...

08/26/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology